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LUNG TRANSPLANTATION
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Background: Lung transplantation is the only treatment modality that provides a survival advantage in
pulmonary fibrosis, but many patients deemed suitable will die awaiting lung transplantation. While donor
organ shortage undoubtedly contributes to this, late referral to the transplant centre may also play a role. This
study investigates factors influencing the chance of patients with pulmonary fibrosis reaching lung
transplantation.
Methods: A single-centre retrospective review of patient demographic data, assessment investigations and
subsequent clinical outcomes was performed for patients with pulmonary fibrosis assessed for lung
transplantation over a 5-year period.
Results: Between March 1999 and March 2004, 129 patients with pulmonary fibrosis underwent formal
transplant assessment. Sixty-nine were accepted and listed for lung transplantation. Of these, 17 were
transplanted, 37 died while waiting, 4 were removed from the list and 11 were still waiting at the conclusion
of the study. The median waiting time on the list for those transplanted was 103 days (range 6–904)
compared with 125 days (range 2–547) for those who died while on the list (p = 0.65). There was no
significant difference in age, spirometry, total lung capacity, gas transfer measures or 6 min walk distance
between those who died waiting and those transplanted. However, time from onset of symptoms to transplant
assessment was significantly shorter in those who died on the waiting list (median 29 months (range 2–120))
than in those transplanted (median 46 months (range 6–204), p = 0.037).
Conclusion: Patients with pulmonary fibrosis who died awaiting transplantation had similar disease severity
at assessment as those who achieved transplantation. However, the interval between symptom onset and
transplant referral was significantly shorter in those who died while on the waiting list, suggesting they had
more rapidly progressive disease. The rate of disease progression appears to be a more sensitive indicator
for transplantation referral than any single physiological measure of disease severity and should act as an
important trigger for early transplant referral.
P
ulmonary fibrosis is a progressive debilitating restrictive
lung disease which, in most cases, is fatal within 3–5 years
of diagnosis.1–4 It is currently recommended that patients
diagnosed with pulmonary fibrosis initially receive treatment
with corticosteroids and immunosuppressive therapy.5 There is,
however, no evidence that this improves survival or reduces the
rate of disease progression. Lung transplantation is the only
treatment modality that provides an actuarial survival advan-
tage in this population.6 The progressive nature of this disease
and the short interval between diagnosis and death make this
therapeutic option available only to a limited number of
younger patients. The transplant process begins with referral
to a specialist transplant centre. Those without an absolute
contraindication are thereafter admitted for detailed inpatient
assessment. Patients accepted onto the active waiting list will
wait on average 12–18 months for a suitable donor organ in the
UK.7 Consequently, many patients never achieve transplanta-
tion and die while on the waiting list. While donor organ
availability undoubtedly contributes to this, patients with
pulmonary fibrosis have the highest waiting list mortality of
all patients awaiting lung transplantation,8 and the unpredict-
able natural history of this disease—together with late referral
for transplant assessment—may play an important role in this
statistic.
Timely assessment is important in all patients under
consideration for lung transplantation, none more so than
those with pulmonary fibrosis in whom the window of
opportunity for transplant may be as little as 22 months.9
Referral criteria suggest that all patients under the age of
65 years who are symptomatic and have failed to respond to
steroid and immunosuppressive therapy should be considered
for transplantation.10 More specifically, a vital capacity of ,60%
predicted or transfer factor of ,50% predicted should trigger
referral. Waiting list mortality has remained high despite these
guidelines, and it has been suggested that they do not
adequately allow for the unpredictable and progressive nature
of this disease. New guidelines published recently have
attempted to address this issue, and suggest that all patients
with usual interstitial pneumonia (UIP), irrespective of vital
capacity, or fibrotic non-specific interstitial pneumonia (NSIP)
should be assessed.11 However, such criteria are broad and
require firm histological diagnosis that may not be easily
accessible to all referring clinicians. In view of this, we reviewed
the experience at our centre over a 5-year period, comparing
those who died while on the waiting list with those who
reached transplantation. Our principal aim was to identify
objective differences that may help refine referral criteria and
subsequently impact on survival in this population.
METHODS
A retrospective review of all patients with pulmonary fibrosis
who underwent formal inpatient assessment for lung trans-
plantation at our centre between March 1999 and March 2004
Abbreviations: IIP, idiopathic interstitial pneumonia; IPF, idiopathic
pulmonary fibrosis; NSIP, non-specific interstitial pneumonia; PaO2, PaCO2,
arterial oxygen and carbon dioxide tensions; PASP, pulmonary artery
systolic pressure; UIP, usual interstitial pneumonia
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was performed. Patient case notes were used to extract baseline
demographic data, histopathological diagnosis, ABO blood
group, body mass index and the results of pulmonary function
tests, arterial blood gas measurement and unencouraged 6 min
walk test distance. Patients were categorised as having
idiopathic pulmonary fibrosis (IPF)/UIP or non-IPF because
of the tendency of IPF/UIP to run a more rapidly progressive
course. The diagnosis of IPF was based on the characteristic
findings on biopsy and high-resolution CT scanning in those
who died and from the explant pathology in those transplanted.
In some cases where it was unclear which subtype of idiopathic
interstitial pneumonia (IIP) was present, patients were
assigned ‘‘unclassified IIP’’.
The clinical course of those listed for transplantation was
followed thereafter until September 2004. In addition, we
examined the length of time between each stage in the
transplant process: (1) symptom onset to assessment; (2)
assessment to listing; and (3) listing to transplantation.
Our aims were to identify objective differences in demo-
graphic measures, physiological measures and clinical course
between those transplanted and those who died on the waiting
list in order to refine referral criteria.
Analysis of data
All demographic and clinical data (excluding static lung
volumes and transfer factor) are expressed as mean (SD). All
remaining data are expressed as median (range). Statistical
analysis was performed using the Student unpaired t test for
parametric data, Mann-Whitney U test for non-parametric
data, and x2 test and Fisher exact test. (Microsoft Excel and
Arcus Quickstat). A p value of ,0.05 was considered
significant.
RESULTS
One hundred and twenty-nine patients (92 men) of mean (SD)
age 53 (7) years with pulmonary fibrosis, referred from 54
centres, underwent formal inpatient assessment between
March 1999 and March 2004. Median time from symptom
onset to first transplant assessment was 36 months (range 2–
240). Of these 129 patients, 69 (53%) were listed for
transplantation. Of the remaining 60 patients who were not
listed, only 3 were deemed too unwell at the time of
assessment. Thirty of the 60 not listed had significant co-
morbidities which acted as a contraindication to transplanta-
tion, the commonest of which were ischaemic heart disease and
obesity. Nineteen of the 60 were deemed too well for
transplantation at the time of assessment. Importantly, we
found no significant difference in spirometry or static lung
volumes, exercise capacity or degree of hypoxia between those
listed and those not. However, those who were not listed had a
significantly higher transfer factor, indicating that this group
had less advanced disease.
Of the 69 patients listed for transplantation, 37 (54%) died
while on the waiting list while 17 (25%) were transplanted.
Eleven patients remained alive on the list at the end of the
study and 4 were removed from the list (fig 1).
Fifteen (88%) of those transplanted and 27 (73%) of those
who died while on the waiting list had a diagnosis of IPF/UIP
based on pathology with or without radiology (table 1). In five
patients who died we were unable accurately to assign a
subtype of IIP and have classified them as ‘‘unspecified IIP’’.
There was no significant difference in the proportions with IPF
and non-IPF between those transplanted and those who died
while on the waiting list (p = 0.3, Fisher exact test).
Time course of assessment, list ing and transplantation
The median time from symptom onset to initial lung
transplantation assessment was significantly shorter in patients
who died while on the waiting list than in those who
underwent transplantation (29 months (range 2–120) vs
46 months (range 6–204); p = 0.037, Mann-Whitney U test).
There was no significant difference between patients who died
on the waiting list and those who were transplanted in time
from assessment to listing (median 60 days (range 4–998) vs
48 days (range 7–305); p = 0.32, Mann-Whitney U test). The
two groups spent similar lengths of time on the transplant
waiting list (median 103 days (range 6–904) for those
transplanted vs 125 days (range 2–547) for those who died
on the waiting list; p = 0.65, Mann-Whitney U test).
Baseline demographic data
There was no significant difference in age, 6 min walk distance,
desaturation on walk test and body mass index between those
who died while on the waiting list and those who underwent
transplantation (table 2). An arterial blood gas analysis was
performed on all patients at transplantation assessment. For
clinical reasons it was necessary to perform this test in some
while receiving supplementary oxygen. Therefore, in addition to
comparing the degree of hypoxia between those transplanted
and those who died while on the waiting list, we allocated
patients receiving oxygen to have an arterial oxygen tension
(PaO2) ,8 kPa (indicating respiratory failure) and compared
those with PaO2 ,8 kPa with those with PaO2 .8 kPa. There
was no significant difference in PaO2 and PaCO2 (table 2) and in
the proportion with PaO2 ,8 kPa and .8 kPa (p = 0.5, x
2 test)
between those transplanted and those who died while on the
waiting list. Lung function was also compared as an objective
marker of disease severity. There was no difference in mean
percentage predicted forced expiratory volume in 1 s or vital
capacity and no difference in median total transfer factor,
transfer factor corrected for alveolar volume or total lung
capacity between those transplanted and those who died while
on the waiting list, among those who were able to complete
reliable lung function testing (table 2).
In some cases patients were unable to complete full testing as
illustrated in table 2. We therefore investigated by x2 analysis
and Fisher exact tests whether there were significant differ-
ences in the proportion of patients transplanted and those who
died while waiting in terms of who could and could not
complete tests (table 3). No significant differences were found,
except for the measurement of vital capacity where those
transplanted were less likely to be able to perform this
manoeuvre.
Presence of pulmonary hypertension
Echocardiograms were performed at assessment on all patients
to investigate the incidence and degree of concomitant
pulmonary hypertension. Adequate views in order to make an
assessment of pulmonary artery pressure were available in 119
Figure 1 Flow chart showing outcomes for patients with pulmonary
fibrosis undergoing formal lung transplant assessment during the 5-year
period of the study.
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cases (92%). A pulmonary artery systolic pressure (PASP) of
.50 mm Hg estimated via tricuspid regurgitant velocity was
taken as evidence of pulmonary hypertension. Sixteen patients
(30%) had documented pulmonary hypertension. We found no
significant difference in the presence or absence of pulmonary
hypertension between those transplanted and those who died
on the waiting list (p = 0.2, x2 test). In addition, among those
with documented pulmonary hypertension, there was no
difference in severity (mean (SD) estimated PASP 59
(10) mm Hg (7 patients transplanted) vs. 65 (11) mm Hg (9
patients died on list) (p = 0.3, unpaired t test).
Blood group
Thirty-seven patients who were blood group O were listed, of
whom only 5 were transplanted. In contrast, 9 of the 25
patients with blood group A received a transplant and 3 of 5
with blood group B were transplanted (p = 0.042, x2 test). No
patients with blood group AB received a transplant in this
cohort.
DISCUSSION
Patients with pulmonary fibrosis have the highest waiting list
mortality of all those awaiting lung transplantation, and new
more sensitive triggers to determine the optimal timing of
transplant referral are urgently needed. In this study we found
that patients who died while on the transplant waiting list had
similar disease severity based on spirometry, static lung
volumes, gas transfer factor, degree of hypoxia, incidence of
pulmonary hypertension and 6 min walk test to those who
achieved transplantation. However, those who died waiting
were referred earlier, with a significantly shorter interval
between symptom onset and referral for transplantation
assessment. These findings suggest that those who died on
the waiting list reached the level requiring transplantation
more rapidly. There was no significant difference between
groups in time spent on the waiting list. From these
observations, we believe that those who died on the waiting
list had more rapidly progressive disease, with a shorter interval
from symptoms to assessment, and subsequent continued rapid
decline while on the waiting list. In further support of this
theory, we found no significant difference in time between
assessment and listing, and listing and transplantation (ie, days
spent on the transplant list) between the two groups. Thus,
delays in listing and longer wait times on the transplant list do
not account for the excess mortality in those on the waiting list.
These findings are in agreement with a recently published
smaller study that showed no difference in conventional
physiological predictors but found a similar difference in time
from diagnosis to referral.12 Timmer et al13 also noted a trend
towards shorter time from diagnosis to referral for patients who
died on the waiting list, but these differences (43.2 months
among those alive on the waiting list vs 20.9 months among
those who died) did not reach significance. These studies
support our hypothesis that the rate of disease progression has
an important role in determining the chance of achieving
transplantation. Collard et al14 showed that changes in dyspnoea
score, total lung capacity, vital capacity and oxygen saturation
over 6 months were predictive of survival and advocated that
such change may provide more accurate prognostic information
than baseline physiological measurements alone. Hanson and
colleagues15 reported that changes in vital capacity and single
breath transfer factor after 1 year of treatment strongly
predictive of survival time in patients with IPF. A 10% reduction
in vital capacity or 20% reduction in single breath transfer
factor after 1 year predicted poorer survival than those patients
with unchanged or improved tests. Data were, however, only
compared at 1 year so the actual rate of physiological decline
and the impact on survival remains unknown.
The pathological classification in pulmonary fibrosis is a most
informative guide with regard to prognosis and an accurate
diagnosis is always sought.16 Diagnosis has been refined by the
new classification system of IIP.16 Patients were assigned a
Table 1 Diagnoses of transplanted patients and those who
died while on the waiting list
Diagnosis
Transplanted
(n = 17)
Died on list
(n = 37)
IPF/UIP 15 27
Based on
Biopsy/radiology 15 13
Radiology 0 14
Non-IPF/non-IIP 2 10
IIP unspecified 0 5
CT disease associated 1 2
Hypersensitivity pneumonitis 1 3
Patients are subdivided into those with idiopathic pulmonary fibrosis (IPF)/
usual interstitial pneumonia (UIP) and those with other forms of idiopathic
interstitial pneumonia (IIP) and non-IIP forms of pulmonary fibrosis. Patients
with IPF are classified according to findings on biopsy and radiology as
illustrated above. Data for those transplanted were obtained from explant
pathology.
Table 2 Baseline demographic and clinical data obtained at transplant assessment for those
transplanted and those who died on the waiting list
Transplanted
(n = 17) n
Died on list
(n = 37) n p Value
Age (years) 53 (8) 17 55 (7) 37 0.3
6MWT distance (m) 226 (106) 16 199 (129) 30 0.5
Desaturation on 6MWT (%) 79 (10) 15 74 (19) 28 0.07
Body mass index 25.5 (5.3) 17 26.7 (3.9) 37 0.4
PaO2 (kPa, room air) 7.9 (1.6) 12 7.7 (1.8) 24 0.7
PaCO2 (kPa, room air) 5.4 (0.9) 12 5.0 (0.6) 24 0.1
FEV1 (% predicted) 47 (14) 17 48 (16) 37 0.8
VC (% predicted) 43 (17) 12 44 (17) 37 0.9
TLCO (% predicted)* 25 (16–36) 13 21 (10–104) 21 0.2
KCO (% predicted)* 60 (18–96) 13 50 (22–91) 21 0.2
TLC (% predicted)* 46 (33–86) 15 45 (28–90) 30 0.9
Data shown are mean (SD) or *median (range).
6MWT, 6 min walk test; PaO2, PaCO2, arterial oxygen and carbon dioxide tensions; FEV1, forced expiratory volume in
1 s; VC, vital capacity; TLCO, total lung transfer factor; KCO, transfer factor corrected for alveolar volume; TLC, total lung
capacity.
Mean/median values were compared using the unpaired t test or Mann-Whitney U test to detect differences in severity of
disease (significance, p,0.05).
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diagnosis of IPF based on clinical history and characteristic
findings on high-resolution CT scanning and biopsy. However,
as is frequently encountered in clinical practice, despite best
efforts, some patients do not receive a firm diagnosis as
evidenced by those with ‘‘unspecified IIP’’. Thus, even with
greater correlation between histology and clinicoradiological
findings, a firm diagnosis is not always reached even after
biopsy.12 17 The presence of another causative factor (such as
connective tissue disease or exposure to asbestos) can make a
correct diagnosis more elusive. In this study, two patients
whose pretransplant diagnosis was connective tissue disease-
associated fibrosis and two who were thought to have NSIP and
desquamative interstitial pneumonia, respectively, were con-
firmed as having UIP when the pathology of their explanted
lung was reviewed.
UIP is the commonest form of IIP and has the worst
prognosis18; however, other forms are also referred for
transplantation as witnessed in this study. Evidence suggests
that the survival advantage conveyed by NSIP does not emerge
until 18–24 months after diagnosis.19 Clinicians should not be
falsely reassured by a diagnosis of NSIP as these patients can be
misdiagnosed or present with rapidly progressive phenotypes
that mimic UIP. Importantly, most patients referred for
transplantation come from centres without specific expertise
or services in fibrotic lung disease. The heterogeneous nature of
this cohort of patients and, indeed, the underlying disease
process therefore make our findings pertinent. The rate of
physiological and symptomatic decline in any form of
pulmonary fibrosis appears to provide a simple accessible tool
that may be of greater prognostic value than the underlying
pathological diagnosis in patients considered for transplanta-
tion.
PaO2 is reported to predict survival in this population,
13 but
we found no difference in the degree of hypoxia or the presence
of respiratory failure (as defined by PaO2,8 kPa) in our cohort,
thus supporting our theory that patients who died while on the
waiting list had similar disease severity to those transplanted.
Similarly, the 6 min walk test has been shown to predict poorer
survival,20 with a distance of ,207 m having a fourfold greater
rate of mortality than those with a walk distance greater than
this distance. In our study, while we found no significant
difference between those transplanted and those who died
while on the waiting list, those who died had a mean walk
distance of 199 m which is in keeping with these findings. The
performance of this test on supplemental oxygen may have
allowed some to achieve higher than expected walk distances,
thus masking this result.
The presence of pulmonary hypertension was shown to
correlate with survival in patients with pulmonary fibrosis in a
study by Nadrous and colleagues.21 They stratified patients into
three groups depending on PASP (,35 mm Hg, 36–50 mm Hg,
.50 mm Hg) and then followed them for 4.8, 4.1 and
0.8 years, respectively. Those with PASP .50 mm Hg had a
significantly worse survival when analysed by the Kaplan-
Meier method. In our study we found no difference in the
presence or degree of pulmonary hypertension between those
who died while on the waiting list and those transplanted. The
measurements of PASP obtained by echocardiography may
have been too insensitive to detect a difference between these
two groups.
Importantly, ABO blood group did influence the chance of
achieving transplantation with patients of blood groups A and
B being more likely to receive a transplant. While this finding
should not be directly used in referral criteria, it may have a role
in the decision-making process at transplant assessment in
group O patients who are moving beyond the transplant
window of opportunity, directing treatment towards a palliative
approach.
The use of explant lung pathology to establish classification
of IIP in those transplanted is by definition limited to only one
group. This may introduce bias. We took this strategy in order
that those transplanted were not assumed to have forms of
pulmonary fibrosis with a better prognosis than UIP/IPF.
Incomplete data are inevitable in this retrospective ‘‘real life’’
observational study of clinical practice. To investigate any
confounding this might cause, we examined whether signifi-
cant differences existed in the proportions of those able to
complete tests and those not (ie, whether disease severity in
either group was masked by incomplete data). We found no
such difference, except for vital capacity, where those trans-
planted were less able to complete the manoeuvre. Thus, at
assessment, we believe that all patients accepted onto the
transplant waiting list had similar disease severity.
This retrospective review encounters the biases and limita-
tions that feature in all such studies. The data were, however,
collected prospectively during detailed inpatient assessment,
with all tests performed over a 4-day period. We acknowledge
that the data on time to referral depends on accurate referral
information. Another limitation is the lack of serial spirometric
and gas transfer measures, providing information on the actual
rate of decline in lung function. These data are not currently
available as patients on the transplant waiting list do not
generally have serial measures of lung function performed
routinely as such repeated tests were previously thought to be
Table 3 Comparison of number of patients in each group able to complete full baseline
demographic and clinical data at assessment for those transplanted and those who died on the
list using x2 analysis and Fisher exact testing where appropriate (p,0.05)
Patients transplanted who
completed the test
Patients who died
awaiting transplantation
who completed the test
p Value (those
completing tests
vs those not)
6MWT 16 30 0.41
Desaturation on 6MWT 15 28 0.47
PaO2 12 24 0.76
PaCO2 12 24 0.76
FEV1 17 37 1
VC 12 37 0.002
TLCO 13 21 0.23
KCO 13 21 0.23
TLC 15 30 0.70
6MWT, 6 min walk test; PaO2, PaCO2, arterial oxygen and carbon dioxide tensions; FEV1, forced expiratory volume in
1 s; VC, vital capacity; TLCO, total lung transfer factor; KCO, transfer factor corrected for alveolar volume; TLC, total lung
capacity.
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of limited value. It could also be considered that these
observations simply reflect local practice in the UK, although
recent changes in the organ allocation system in the USA make
these observations internationally relevant.
In conclusion, we have shown that patients who died on the
lung transplant waiting list were referred earlier than those
who were transplanted. These two groups did not differ
significantly in lung function indices, 6 min walk test or degree
of hypoxia, suggesting that when assessed they had similar
disease severity. We believe that those who died on the waiting
list had more rapidly progressive disease as evidenced by the
shorter time from symptom onset to assessment. This study
suggests that the rate of progression of disease may provide an
indication of when to refer patients with pulmonary fibrosis for
lung transplantation assessment. Further work is now required
to investigate the rate of change in these patients and to
determine the magnitude and velocity required to trigger
transplant referral.
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